- Cambridge Cognition Holdings
- 13 April 2026 12:55:38
Source: Sharecast
The AIM-traded neuroscience technology group said new sales orders rose 73% to £12.8m from £7.4m in 2024, while its year-end order book increased 21% to £16.5m.
Revenue fell 10% to £9.4m from £10.3m, with the company reporting an adjusted EBITDA loss of £0.5m compared with a £43,000 loss the previous year.
The group said the revenue decline was due to a weak opening order book, although prior cost reductions helped limit the impact on profitability.
It added that operating cashflow turned positive during the year following a period of cash outflows.
Cambridge Cognition said it strengthened its balance sheet through a £1.1m placing in August, ending the year with cash of £1.1m, compared with £1.3m at the end of 2024.
Borrowings were reduced to £0.9m from £1.9m, resulting in a net cash position of around £0.3m versus net debt of £0.6m a year earlier.
The firm said it made progress across four market segments, reinforcing its position in clinical studies and academic research while expanding into professional healthcare and consumer health and wellness markets.
Looking ahead, the group said it expected to deliver revenue of £9.5m in 2026, supported by its current order book and revenue recognised to date, up from £8.8m expected at the end of 2025.
It said further sales orders in the remainder of the year were not yet included in the outlook, adding that it expected revenue growth in the current year.
“2025 saw a return to growth in new sales orders and clear progress in strengthening the foundations of the business,” said chief executive Rob Baker.
“We have enhanced our commercial execution, maintained high-quality operational delivery and expanded into professional healthcare and consumer health & wellness markets, significantly increasing our addressable opportunity.
“Whilst revenue and profitability reflect the prior year's reduced order book, the recovery in new business, combined with a healthy pipeline and early progress in our new markets, position us for growth in revenue, earnings and cash generation in 2026.”
At 1054 BST, shares in Cambridge Cognition Holdings were up 2.56% at 40p.
Reporting by Josh White for Sharecast.com.
See latest RNS on Investegate